21-04-2026, 06:00

Essential Pharma 旗下公司 Renaissance Pharma Limited 用于治疗高危神经母细胞瘤的 Daretabart (hu1418K322A) 获得 FDA 快速通道认定，并通过 IND 审评

Notified -
Globe Newswire21-04-2026, 06:00
6-02-2025, 15:00

Essential Pharma and Clinigen Expand Collaboration to Improve Patient Access in JAPAC

Notified -
Globe Newswire6-02-2025, 15:00
12-12-2024, 14:00

Essential Pharma announces €900 million recapitalisation through a Gyrus Capital Continuation Vehicle led by AlpInvest and new strategic financing from Sixth Street

Notified -
Globe Newswire12-12-2024, 14:00
17-04-2024, 13:00

Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules
Globe Newswire17-04-2024, 13:00
9-04-2024, 13:00

Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma

Notified -
Globe Newswire9-04-2024, 13:00
8-01-2024, 14:00

Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva
Globe Newswire8-01-2024, 14:00